These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21083131)

  • 1. Challenges in developing antidrug antibody screening assays.
    Dodge R; Daus C; Yaskanin D
    Bioanalysis; 2009 Jul; 1(4):699-704. PubMed ID: 21083131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
    Zhong ZD; Clements-Egan A; Gorovits B; Maia M; Sumner G; Theobald V; Wu Y; Rajadhyaksha M
    AAPS J; 2017 Nov; 19(6):1564-1575. PubMed ID: 29063411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.
    Gupta S; Devanarayan V; Finco D; Gunn GR; Kirshner S; Richards S; Rup B; Song A; Subramanyam M
    J Pharm Biomed Anal; 2011 Jul; 55(5):878-88. PubMed ID: 21531522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-PCR assays for immunogenicity testing.
    Spengler M; Adler M; Jonas A; Niemeyer CM
    Biochem Biophys Res Commun; 2009 Sep; 387(2):278-82. PubMed ID: 19577544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H; Xu W; Titsch CA; Furlong MT; Dodge R; Voronin K; Allentoff A; Zeng J; Aubry AF; DeSilva BS; Arnold ME
    Anal Chem; 2014 Mar; 86(5):2673-80. PubMed ID: 24506335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs.
    Wessels U; Zadak M; Weidmann AM; Stuchly T; Stubenrauch KG
    AAPS J; 2022 Nov; 25(1):2. PubMed ID: 36414857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.
    Sloan JH; Conway RG; Pottanat TG; Troutt JS; Higgs RE; Konrad RJ; Qian YW
    Bioanalysis; 2016 Oct; 8(20):2157-68. PubMed ID: 27593891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.